Trial record 1 of 111 for:    Radiation with Androgen Deprivation
Previous Study | Return to List | Next Study

Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Washington
ClinicalTrials.gov Identifier:
NCT01023061
First received: November 30, 2009
Last updated: February 11, 2014
Last verified: February 2014
  Purpose

This phase II trial studies the side effects and how well abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy works in treating patients with localized or locally advanced prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, leuprolide acetate, and goserelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving abiraterone acetate and leuprolide acetate or goserelin before or together with radiation therapy may be an effective treatment for prostate cancer.


Condition Intervention Phase
Adenocarcinoma of the Prostate
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer
Stage III Prostate Cancer
Stage IV Prostate Cancer
Drug: abiraterone acetate
Drug: prednisone
Drug: leuprolide acetate
Other: laboratory biomarker analysis
Radiation: external beam radiation therapy
Drug: goserelin acetate
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Radiation With Androgen Deprivation (RAD): Abiraterone Acetate, Prednisone and LHRH Agonist Prior to Radiation Therapy

Resource links provided by NLM:


Further study details as provided by University of Washington:

Primary Outcome Measures:
  • Incidence of acute and chronic grade 3 or greater toxicity as evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 [ Time Frame: Up to 24 months after initiation of radiation therapy ] [ Designated as safety issue: Yes ]
    The distribution of time to late adverse events (observed severities of adverse events over time) will be estimated using the Kaplan-Meier method.

  • Levels of dihydrotestosterone (DHT) and testosterone in prostate biopsy sample assessed by mass spectrometry [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    The levels from patients treated in this study will be compared to a control set of biopsies acquired from a separate but similar population of men with intermediate and high risk prostate cancer treated with three months of combined LHRH agonist and bicalutamide as part of standard of care.


Secondary Outcome Measures:
  • Inhibition of androgen-regulated gene expression and increased apoptotic cell death [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Assessed by immunohistochemistry, cDNA microarray analysis, RT-PCR for androgen regulated genes (PSA, FKBP5, NKX3.1, AR, clusterin, acid phosphatase) from prostate biopsy samples.

  • Median time to PSA progression [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Defined as the date of an increase of 2ng/mL or more above the PSA nadir achieved after completion of RT with the date of progression defined as the date on which that PSA was measured. Distribution of time-to-event variables will be estimated using the Kaplan-Meier product-limit method. Estimated with two-sided 95% confidence intervals.

  • Median time to PSA progression [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Defined as the date of an increase of 2ng/mL or more above the PSA nadir achieved after completion of RT with the date of progression defined as the date on which that PSA was measured. Distribution of time-to-event variables will be estimated using the Kaplan-Meier product-limit method. Estimated with two-sided 95% confidence intervals.


Estimated Enrollment: 25
Study Start Date: March 2010
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (antihormone therapy and radiation therapy)
Patients receive abiraterone acetate PO and prednisone PO QD for 24 weeks. Patients also receive leuprolide acetate or goserelin in weeks 1 and 13. Patients undergo external beam radiotherapy starting in week 15 for 8.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Drug: abiraterone acetate
Given PO
Other Names:
  • CB7630
  • Zytiga
Drug: prednisone
Given PO
Other Names:
  • DeCortin
  • Deltra
Drug: leuprolide acetate
Given via injection
Other Names:
  • Enantone
  • LEUP
  • Lupron
  • Lupron Depot
Other: laboratory biomarker analysis
Correlative study
Radiation: external beam radiation therapy
Undergo radiotherapy
Other Name: EBRT
Drug: goserelin acetate
Given via injection
Other Names:
  • ICI-118630
  • ZDX
  • Zoladex

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the safety of abiraterone (abiraterone acetate) and prednisone with luteinizing hormone-releasing hormone (LHRH) agonist given as neoadjuvant and concurrent therapy with external beam radiation in patients with localized prostate cancer.

II. To determine whether pharmacologic suppression of the prostatic androgen axis by inhibition of androgen production with abiraterone can decrease tissue androgen levels to below those observed with gonadotropin-releasing hormone (GnRH) agonist suppression of testicular androgens.

SECONDARY OBJECTIVES:

I. To determine whether treatment with abiraterone acetate with LHRH agonist will be more effective than LHRH agonist with bicalutamide in inducing inhibition of androgen-regulated gene expression and increased apoptotic cell death as assessed by immunohistochemistry, complementary deoxyribonucleic acid (cDNA) microarray analysis and reverse transcription-polymerase chain reaction (RT-PCR).

II. To evaluate time to prostate-specific antigen (PSA) progression in patients treated with LHRH agonist with abiraterone acetate.

OUTLINE:

Patients receive abiraterone acetate orally (PO) and prednisone PO once daily (QD) for 24 weeks. Patients also receive leuprolide acetate or goserelin in weeks 1 and 13. Patients undergo external beam radiotherapy starting in week 15 for 8.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 5 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and able to provide written informed consent
  • Patients must allow biopsy prior to neoadjuvant therapy and at the time of fiducial placement
  • Written Authorization for Use and Release of Health and Research Study Information has been obtained
  • Histologically proven adenocarcinoma of the prostate
  • Patients must be candidates for short or long term androgen deprivation in combination with external beam radiotherapy (RT) based on the following criteria:

    • Intermediate Risk Disease: T2b/c, or Gleason 7, or PSA 10-20
    • High Risk Disease: Gleason 8-10, or PSA > 20, or T3/4
  • Patients may not have received any prior pharmacologic therapy or radiation therapy (RT) for prostate cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Karnofsky >= 60%
  • Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the androgen axis will be determined following review of their case by the Principal Investigator
  • White blood cell count: >= 3,000/mm^3
  • Absolute granulocyte count: >= 1,000/mm^3
  • Platelets: >= 100,000/mm^3
  • Hemoglobin >= 10g/dL
  • Potassium >= 3.5 mmol/L
  • Serum creatinine: =< 1.5 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) < 2.5 x ULN
  • Alanine transaminase (ALT) < 2.5 x ULN
  • Total bilirubin: =< 1.5 x ULN (except for patients with documented Gilbert's disease)

Exclusion Criteria:

  • Patients may not be receiving any investigational agents
  • Concurrent enrollment in another clinical investigational drug or device study is prohibited
  • The concurrent administration of other anticancer therapy, including cytotoxic or hormonal agents (except LHRH agonists), or immunotherapy, is prohibited during neoadjuvant concurrent and adjuvant therapy
  • Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible
  • Patients with histologic evidence of small cell carcinoma of the prostate will not be eligible
  • Patients with hypogonadism or severe androgen deficiency as defined by serum testosterone less than 100 ng/dL will not be eligible
  • History of pituitary or adrenal dysfunction
  • Patients who are receiving any androgens, estrogens or progestational agents, or who received any of these agents within the 6 months prior to evaluation will not be eligible
  • Patients who are taking drugs which affect androgen metabolism (e.g. spironolactone, ketoconazole, finasteride, dutasteride) will not be eligible
  • Concomitant therapy with any of the following listed is prohibited: 5 alpha-reductase inhibitor (finasteride, dutasteride); ketoconazole, diethylstilbestrol, PC-SPES, and other preparations such as saw palmetto thought to have endocrine effects on prostate cancer; radiopharmaceuticals such as strontium (89Sr) or samarium (153Sm); Aldactone, Spironol (spironolactone); estrogens, testosterone, progesterones, herbal medications
  • Patients who received any of these agents within the 6 months prior to evaluation will be reviewed for eligibility by the Principal Investigator on a case by case basis
  • Use of other investigational drug therapy for any reason is prohibited
  • Patients with inflammatory bowel disease or other autoimmune conditions which might affect the radiated colon or rectum
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia which is symptomatic or requires active therapy, recent deep venous thrombosis, pulmonary emboli, cerebrovascular accident or ischemia will not be eligible
  • Patients who have chronic active hepatitis or acute hepatitis will not be eligible
  • Patients with dementia/psychiatric illness/social situations that would limit compliance with study requirements or would prohibit the understanding and/or giving of informed consent will not be eligible
  • Patients with medical conditions, which, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained will not be eligible
  • Uncontrolled hypertension within the screening period (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg)
  • Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy
  • History of congestive heart failure of any severity
  • Other active malignancy, except non-melanoma skin cancer and superficial bladder cancer
  • History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
  • Patients with diabetes not controlled with diet alone (i.e. requiring insulin or oral hypoglycemics)
  • Patients unwilling to use contraceptives while on study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01023061

Locations
United States, Washington
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
MultiCare Regional Cancer Center - Tacoma
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
University of Washington
Investigators
Principal Investigator: Robert Montgomery Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
  More Information

No publications provided

Responsible Party: University of Washington
ClinicalTrials.gov Identifier: NCT01023061     History of Changes
Other Study ID Numbers: 7048, NCI-2009-01346, 7048 - AbiRAD, 7048, P30CA015704
Study First Received: November 30, 2009
Last Updated: February 11, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Adenocarcinoma
Prostatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Prednisone
Leuprolide
Goserelin
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Anti-Inflammatory Agents
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents

ClinicalTrials.gov processed this record on April 22, 2014